Browse Newsroom

InsuLife Welcomes Dr. Makarand Jawadekar to the Scientific Advisors Team

April 28, 2024

“We are proud and excited to announce that Dr. Makarand Jawadekar has joined InsuLife’s Scientic Advisors team” says Aage Naerdal, CEO of InsuLife.

Dr. Makarand (Mak) Jawadekar devoted most of his working years at Pfizer, Inc. based in Groton-New London, Connecticut for 28 consecutive years. During his career span at Pfizer, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for Drug Delivery Technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics, under the guidance of Prof. Edward Rippie at the University of Minnesota.

His 28+ years of experience with Pfizer Global R&D specifically includes Solids R&D, Drug Product formulation/Dosage Form/ Drug Delivery development, Clinical Trials Supply Manufacturing, Scale-up and Technology Transfer & Research Pharmacy functions. He helped create various Pharma R&D Partnerships, JVs, and Collaborations. He was also involved in conducting ‘Due-Diligence’ activities as a subject matter expert on behalf of Pfizer for eventual acquisition of companies or their IP assets. He managed several internal functions/groups within R&D for many years. He was the formulation Lead for ZOLOFT, ZITHROMAX and NORVASC Tablets.  Also notable was Dr. Jawadekar’s relevant contributions during his tenure at Pfizer R & D was his involvement in the formulation of Exubera, the first inhaled insulin product.

“I am excited to be joining the distinguished team of advisors and management at InsuLife as their Scientific Advisor, looking forward to supporting InsuLife's "Transdermal Insulin" pathway, as a commercially successful approach, which would be a great win for people with diabetes across the globe”, says Dr. Jawadekar.

Post Pfizer career, he worked with KKR, a Private Equity group in New York, for acquisition of Capsugel division from Pfizer which Pfizer divested later in 2011. Mak has presented at many professional meetings and has participated in various Panel Discussions/Round Tables around the globe.

He is Advisor to the Family office of Saudi Arabian Prince Salman Bin Faisal Bin Abdul Aziz Al Saud, as well as serves on several Strategic & Scientific Advisory Boards in the Pharmaceutical industry

“To have Mak as an Advisor to our company is an honour, and it will cement our ongoing development of INS-2301 into clinical development. We really look forward to working with him and harvest from his life-long competence and standing in the global pharmaceutical world”, says Mr. Naerdal.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved
cross